Rocket Lab RKLB stock prediction: $104 bull, $76 base, $41…

Rocket Lab (NASDAQ: RKLB) trades at $66.18, down 56.2% from its $151.00 intraday high set on 27 May 2026 — and almost none of that decline was caused by anything Rocket Lab did. The company reported record quarterly revenue, guided to another record, and announced the largest acquisition in its history during the same window the stock halved. What actually broke the stock was the arrival of a $2 trillion competitor on the same exchange, one Blue Origin explosion, and a leveraged-ETF unwind. Our 12-month view: $104 bull, $76 base, $41 bear.

Here is the fact that reframes the entire chart. RKLB is down 56.2% from its high — and still up 37.5% over the last twelve months, and up 76.2% from its 52-week low of $37.57. This was not a collapse. It was the round-trip of a melt-up that began when SpaceX filed its IPO prospectus on 20 May 2026 and ended when SpaceX actually listed. The business that exists at $66 is materially larger than the business that existed at $48 a year ago. The multiple is what changed.

What actually happened: a liquidity event wearing a fundamentals costume

The sequence is unusually legible, and it is worth walking date by date, because the market has spent three months pricing Rocket Lab for problems that belong to other companies.

On 20 May 2026, SpaceX filed its IPO prospectus. Money rotated aggressively into listed space pure-plays as a proxy trade. When Starship V3 lost its Super Heavy booster on 21–22 May, that rotation accelerated rather than reversed — a stumble at SpaceX read as an opportunity for everyone else. Rocket Lab helped itself along the way, announcing a $90 million U.S. Space Force space-domain-awareness contract and closing its Motiv Space Systems acquisition in the same week. RKLB topped out at $151.00 intraday on 27 May.

Then, late on 28 May, Blue Origin’s New Glenn exploded on the pad at Cape Canaveral during a hot-fire test of its seven BE-4 engines, heavily damaging its only operational New Glenn pad. The read-through was immediate and indiscriminate. As Yahoo Finance reported on 29 May, “Space stocks have been bid up aggressively over the past month, with the Procure Space ETF up 24% in the past five days and the UFO ETF higher by more than 100% over six months as investors position for SpaceX’s initial public offering.”

RKLB fell 14.70% on 1 June. It fell another 10.79% on 12 June — on 63.4 million shares, the heaviest volume in its trailing year — which was the day SpaceX itself began trading, raising roughly $75 billion and closing at a $2.11 trillion market capitalisation. The mechanism was not subtle. As The Motley Fool wrote that day: “While SpaceX had a strong, bullish day of trading, most other space stocks actually got hit with big sell-offs. With SpaceX hitting the market, it looks like a substantial number of investors sold stakes in other space companies in order to free up funds to invest in Elon Musk’s company upon its public debut.”

That is a funding-flow event, not a re-rating of Rocket Lab’s cash flows. We covered the same dynamic across the sector in our analysis of the SpaceX effect on space stocks.

The June unwind: index inclusion, then forced selling

Between 18 and 25 June, RKLB fell 24.76%. Two things overlapped, and both are technical.

First, Rocket Lab joined the Nasdaq-100 effective Monday 22 June, in the annual reconstitution alongside CoreWeave and Nebius. It fell 6.48% that day — a textbook sell-the-news, where index funds have already bought and everyone else takes the exit liquidity.

Second, and larger: the post-IPO SpaceX unwind was being amplified by leveraged single-stock products. Per 24/7 Wall St on 24 June, “SPCX fell 22.64% over the week ending June 23, from $201.80 to $156.11… SPAL, the 2x long product, dropped 42.51% over the same stretch, from $37.78 to $21.72.” The same report noted that “roughly 11 leveraged or derivative ETFs launched right after SpaceX went public with only a 4% float, layering forced daily rebalancing on top of already-limited tradable supply.”

A 4% float with eleven leveraged products stacked on it produces mechanical selling that spills into every correlated name. Rocket Lab was correlated. That is the whole explanation.

Then July did the rest, and it was macro

RKLB fell 36.10% in July. So did SpaceX, by roughly 36.6% — the two moved almost in lockstep, which is itself evidence that neither move was company-specific. The Motley Fool’s Keith Noonan attributed it to the Iran war re-intensifying: “The war has had a significant upward impact on oil prices, and investors reacted to the possibility that a protracted conflict would push inflation higher and cause the Federal Reserve to raise interest rates in response.” Long-duration, cash-burning growth equities are the first thing sold in a higher-for-longer repricing, and Rocket Lab is exactly that. But the macro explanation only stretches so far, and one control breaks it: over 27 May to 26 June, the ARK Innovation ETF (ARKK) — the purest listed proxy for exactly this kind of long-duration risk appetite — was up 0.2% while RKLB fell 43.7%. ARKK went on to hit a 52-week high on 25 August. This was not the market selling growth. It was capital rotating into the largest space asset ever listed.

The one genuinely company-specific hit came on 16 July, when RKLB dropped 11.61% after Piper Sandler initiated coverage at Neutral with an $83 price target. GuruFocus reported that the move added “to investor concerns over the company’s planned acquisition of Iridium Communications and potential shareholder dilution,” noting the deal “includes about $3.6 billion in bridge financing, prompting some investors to focus on funding needs, execution risks and the possibility of additional share issuance.”

The insider tell nobody has priced properly

Here is the part of this story that has gone almost entirely uncommented, and it is checkable in the filings.

Rocket Lab insiders sold the exact top. Director Alexander R. Slusky sold 60,000 shares on 28 May at $149.10 and $150.00 — one day after the stock printed its $151.00 intraday high — and a further 40,000 shares on 2 June at $123.60. Chief Operating Officer Frank Klein sold 36,860 shares on 28 May in a $143.05–$149.99 range. Founder and CEO Sir Peter Beck then sold 3,275,779 shares for $286.4 million across 6–8 July, per a Form 4 filed 8 July, at prices descending from $101.57 to $81.59 as the stock fell underneath him. (Several outlets have reported that sale at roughly $94 million; the filing’s own line items total $286,410,195.58.)

Two readings are available and an honest analysis has to hold both. The charitable one, and on the evidence the stronger one: Beck’s sale executed automatically under a Rule 10b5-1 plan adopted on 27 March 2026, months before the top, through a family trust — the entire point of such a plan is that the timing is not chosen. He sold about 7% of his holding and retains 40,951,250 Series A preferred shares. He had also days earlier cut his own salary to $1 and forfeited $392,155 of restricted stock, which is not the behaviour of someone extracting value. The uncharitable one applies to Slusky rather than Beck: his 28 May sales were genuinely discretionary, not plan-driven, and they landed one day after the highest print of the year. A third tranche of August selling is pure restricted-stock tax withholding and means nothing at all. These three things are routinely blended into a single “insiders are dumping” narrative; they should not be.

Iridium: the deal the market actually liked

Here is where most coverage of this stock has it backwards, and the timeline settles it.

Rocket Lab was already down 43.7% before the Iridium acquisition was ever announced — and it rose 15.93% on the announcement day. The deal did not break the stock. The stock was already broken by the SpaceX rotation, and the deal was the one thing that briefly reversed it.

What the deal did do is introduce a financing overhang that arrived later, through a specific and checkable mechanism. Rocket Lab’s own merger proxy describes a 25% collar on the stock consideration, with bounds at $67.50 and $112.50. Those are ±25% around a $90.00 reference price. RKLB now trades at $66.18 — 26.5% below the reference and through the bottom of the collar. That is the single most concrete valuation fact in this situation, and it is why the dilution objection has teeth that generic “they issued stock” commentary does not capture.

The bidding history is also more favourable to Rocket Lab than the price suggests. Rocket Lab opened at $42.50 on 15 April 2026 in all stock, moved to $52.00 in June, and closed at $54.00 (half cash, half stock). The only competing mark was a rival bidder at $41.00–$45.00 all cash — which signalled it would bid at the low end absent exclusivity and never submitted a final proposal. Rocket Lab paid up, but it paid up against a real alternative, not against itself.

On the asset: Morgan Stanley’s Kristine Liwag, Overweight with a $105 target, argued that “the transaction materially enhances Rocket Lab’s strategic positioning by expanding its presence beyond launch into satellite connectivity… investors should increasingly evaluate Rocket Lab not solely as a launch company, but as an emerging integrated space platform.” She noted Iridium “posted ~$872mn revenue and ~$495mn EBITDA in 2025A” — more revenue than Rocket Lab generates, and EBITDA that Rocket Lab does not yet produce.

The offsetting pressure is mechanical rather than narrative. Short interest stood at 44,395,701 shares at the 14 August settlement — 7.96% of float, 2.18 days to cover, and up 84% since 31 March. The largest single jump, roughly 8.4 million shares, falls between the 15 and 30 June settlements — bracketing the Iridium announcement almost exactly. That is the signature of merger-arbitrage shorting RKLB against long Iridium, not a directional bear raid, and it explains a meaningful part of the grind lower.

The margin trend nobody is discussing

One genuine operational concern does deserve more attention than it has received, and it is not Neutron.

Rocket Lab’s GAAP gross margin has now been guided down twice in succession: 38.2% in Q1, 36.1% in Q2, and a Q3 guide of 29–31%. That is a second consecutive guided decline, and a roughly nine-point compression from the Q1 print. Management attributes the mix shift to Space Systems ramping, which is a real and defensible explanation — hardware manufacturing carries lower margins than launch services. But an investor paying a platform multiple for a business whose gross margin is compressing toward 30% is making a bet on operating leverage that has not yet appeared in the accounts.

Neutron is the whole bull case, and the market says it slips

Everything above is context. Neutron is the trade.

Rocket Lab’s entire re-rating thesis rests on Neutron — the medium-lift, reusable vehicle that moves the company out of the small-launch niche and into direct competition for the constellation-deployment contracts that currently have exactly one credible Western bidder. Electron is a good business with a real cadence record; the Space Force gave Rocket Lab 24 hours to integrate and launch a satellite in a rapid call-up demonstration, and it delivered. But Electron does not justify a $30 billion valuation. Neutron does.

Which is why the most important number in this article is not on Rocket Lab’s income statement. Polymarket prices “Rocket Lab’s Neutron Rocket Launch by December 31” at 8.5% — and that price fell 7.5 points over the past month. Real money, with real skin, says Neutron does not fly this year.

Beck himself has framed the question the way an investor should. Speaking to Sourcery with Molly O’Shea on 24 August, he said: “I guess the question that that investors and analysts should be asking me, it’s like, Pete, when’s the 10th rocket going to be on the pad?” His answer is that cadence, not first flight, is the real unlock — “by the time you get to rocket 10, your reusability is sorted, all your production sorted, you’re banging out whole stages.” That is correct, and it is also a much longer runway than the equity is priced for.

The numbers: $104 bull, $76 base, $41 bear

Bull — $104 (+57%). Neutron flies successfully in the first half of 2027 and the Iridium acquisition closes without further equity issuance beyond what is already signalled. Backlog above $2.3 billion converts on schedule, Iridium’s ~$495 million of EBITDA lands in the consolidated accounts, and the market re-rates Rocket Lab as an integrated platform rather than a launch vendor. This does not require a new bubble — $104 is still 31% below the May high. It requires the plan to work, and it requires the market to stop treating SpaceX as the cheaper way to own the same theme.

Base — $76 (+15%). Neutron slips into 2027 but stays credible, Iridium closes and is modestly dilutive, and the sector’s post-SpaceX-IPO discount partially unwinds as the leveraged-ETF distortion fades and float normalises. Note the striking divergence here: sell-side consensus has risen from roughly $97 before the Iridium deal to about $111 today, up around 14% while the stock fell 56%. Analysts have not capitulated; the market has. Our $76 base sits deliberately and substantially below consensus, because we think the SpaceX valuation anchor caps the re-rating that consensus still assumes.

Bear — $41 (−38%). Neutron slips again into late 2027 or beyond, the Iridium bridge is refinanced with equity at depressed prices, and rates stay high enough to keep long-duration growth out of favour. This level sits above the 52-week low of $37.57, which is where the stock traded in November 2025 — before the Iridium deal, before Nasdaq-100 inclusion, and before a record quarter. A return to that zone would imply the market has decided Neutron will not fly at all.

What would change our mind

Three specific, observable triggers. First, a dated, hardware-backed Neutron launch commitment — a static fire of the full first stage at Wallops would move the Polymarket line more than any earnings release. Second, the Iridium financing structure: if the $3.6 billion bridge is termed out with debt rather than equity, the dilution objection largely dissolves and the base case moves toward the bull. Third, insider behaviour in reverse — open-market buying by Beck or Slusky at these levels would be the single most informative signal available, precisely because their selling at the top was.

For context on how the rest of the cohort is priced after the same de-rating, see our current views on SpaceX (SPCX), AST SpaceMobile (ASTS) and Intuitive Machines (LUNR).

FAQ

Why did Rocket Lab stock fall so much in 2026?

Almost entirely for reasons external to the company. RKLB peaked at $151.00 on 27 May 2026 during a sector melt-up driven by SpaceX’s IPO filing. It then fell on a Blue Origin pad explosion (28 May), profit-taking before the SpaceX listing (−14.70% on 1 June), the SpaceX IPO itself (−10.79% on 12 June, as investors sold space stocks to fund SPCX), a Nasdaq-100 sell-the-news plus leveraged-ETF unwind (−24.76% across 18–25 June), and a macro rate-fear drawdown in July (−36.10%). Q2 revenue was a record throughout.

Is RKLB stock a buy at $66?

That depends entirely on your view of Neutron’s schedule, and you should be honest with yourself about how little visibility anyone outside the company has. The prediction market currently gives Neutron an 8.5% chance of flying by 31 December 2026. If you believe that is too pessimistic, the risk/reward at $66 against a $104 bull case is attractive. If you think it is about right, the base case of $76 is your realistic ceiling for twelve months. This is analysis, not advice.

What is Rocket Lab’s price target?

Our 12-month view is $104 bull, $76 base and $41 bear against a spot of $66.18. Sell-side consensus was an average of $113.43 across 16 covering analysts as of 16 July 2026, but those targets were struck when the stock was $78.81 and largely predate the July decline, so treat them as stale. Piper Sandler’s $83 Neutral, initiated 16 July, is the most recent published anchor we could verify.

How does the Iridium acquisition affect Rocket Lab shareholders?

It adds roughly $872 million of annual revenue and about $495 million of 2025 EBITDA — more revenue than Rocket Lab itself generates, and profitability Rocket Lab does not yet have. The cost is roughly $8 billion, including about $3.6 billion of bridge financing, and the risk is that equity is issued at a depressed share price to fund it. Dilution at $66 is more than twice as expensive as dilution at $150 would have been. This is the central bear objection and it is legitimate.

When will Neutron launch?

Rocket Lab has filed for a launch permit with a window running 1 July to 31 December 2026, but the market does not believe it. Polymarket prices a launch by 31 December at 8.5%, down 7.5 points over the past month. CEO Peter Beck has publicly reframed the question toward cadence rather than first flight, arguing that the meaningful milestone is “when’s the 10th rocket going to be on the pad” — which implies a multi-year ramp beyond the debut.

This article is informational analysis only and is not investment advice, a recommendation, or a solicitation. Price targets are FinanceFeeds estimates and represent scenario analysis, not forecasts. Spot price of $66.18 is the close of 26 August 2026 per stockanalysis.com. Analyst targets and insider transactions cited are as of their stated dates and may since have changed. Rocket Lab is a pre-profit company with material execution and financing risk; you can lose money. Always do your own research.